Just trying to join some additional dots with our superstar...

Just trying to join some additional dots with our superstar flying under the radar

bioMD Makes Offer for Unlisted Allied Medical
to Create Diversified Healthcare Group

* Offer recommended by Allied Medical Board

* Merged group to focus on growing cash flow businesses and commercialisation of new medical technologies.

*Complementary assets creates a diversified healthcare group

The transaction will create a diversified healthcare group focused on a growing distribution business and the commercialisation of new medical technologies. The acquisition will bring together a product pipeline developing next generation vaccines and tissue engineering technologies, as well as a profitable medical device distribution business.

The new group will include Allied's major investment in DNA Vaccine development company Coridon Pty Ltd, led by Professor Ian Frazer, the developer of the Gardasil cervical cancer vaccine, and bioMD's innovative tissue engineering and regenerative technologies for use in cardiovascular and soft tissue repair surgery.

**********

Prima Biomed Ltd Ann May, 3 - Deutsche Bank Securities, Inc. 36th Annual Healthcare Conference in Boston, in the USA on Wednesday 4th May 2011

Oral HPV Vaccine

* Prima has partnered with Prof. Ian Frazer and Prof. Neil Foster to use dense gas technology for the formulation of an oral HPV vaccine

* The technology reformulates large, irregular particles into smaller, consistent sizes, allowing for higher bioavailability at lower doses of a drug and encapsulation for oral dosing

* Studies with Eudragit - coated lyzosyme completed and
feasibility studies with ovalbumin are ongoing.

Using dense gas technology (lysozyme framework) reduced the particle size seventy-fold and produced a much more regular shape.

* Oral HPV vaccine progress update Q3-Q4 2011
__________

Interesting to also note that Coridon is currently in the pre-clinical phase of evaluating a combined prophylactic and therapeutic HSV-2 vaccine with a view to commencing a human phase 1b clinical trial in late 2011.

Of course HPV and HSV are very different viruses - However I'd assume some major Coridon s/holders by the likes of Andrew Forrester wouldn't expect Prof Frazer to be working independently outside his own company to only benefit another?

Thoughts on this anyone?